A5320: Viral Hepatitis C Infection Long-term Cohort Study (V-HICS)

Study Location:

BaltimoreWashington

Topic:

Hepatitis and HIV

Clinicaltrials.gov Link:

N/A

IRB#:

NA_00092078

Coordinator:

Ilene Wiggins, RN (Baltimore)

Anna Wimpelberg (Washington)

Enrollment:

Closed

Trial Period:

Ongoing

A5320/V-HICS is an observational, prospective, long-term follow-up study in hepatitis C virus (HCV) monoinfected and HCV/HIV-1 coinfected participants who received direct-acting antiviral (DAA) therapy for HCV infection.

Men and women ≥ 18 years old, HCV/HIV-1 coinfected who failed HCV therapy any time after HCV/DAA treatment discontinuation (non-SVR); or HCV monoinfected who failed HCV therapy any time after HCV/DAA treatment discontinuation (non-SVR); or HCV/HIV-1 coinfected participants who achieved a SVR at least 12 weeks after treatment completion; or HCV monoinfected participants who achieved a SVR as at least 12 weeks after treatment completion.

Anna Wimpelberg (Washington)
202-797-3589
awimpelberg@whitman-walker.org


​Ilene Wiggins, RN (Baltimore)
410-614-2766
iwiggin1@jhmi.edu

Categories

Location
Topic

Clinical Trials

A5361s: Pitavastatin to REduce Physical Function Impairment...

A5361s is a prospective study to determine the effects of pitavastatin on physical function. The study will enroll participants...

Read More

A5273: Multicenter Study of Options for Second-Line...

The study is being done with people who are taking their first anti-HIV drug regimen (including an Non-Nucleoside Reverse...

Read More

A5302:  BioBank for Surrogate Marker Research for TB...

Primary Objective To obtain sputum, serum, urine, and peripheral blood mononuclear cells (PBMCs) for central TB biorepository...

Read More

A5345, Identification of Biomarkers to Predict Time to...

Brief Summary: The purpose of this study is to collect information about what happens when people pause, or temporarily stop...

Read More

A5253: Sensitivity and Specificity of Mycobacterium...

An estimated 3 million HIV-infected individuals will enter programs for antiretroviral (ARV) treatment in the coming year, with...

Read More